Julie Anne Smith's most recent trade in Exelixis Inc was a trade of 44,087 Option (right to buy) done . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 44,087 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.50 per share. | 17 Feb 2026 | 44,087 | 20,590 (0%) | 0% | 44.5 | 1,961,872 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.39 per share. | 17 Feb 2026 | 44,087 | 64,677 (0%) | 0% | 19.4 | 854,847 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.19 per share. | 17 Feb 2026 | 42,422 | 63,012 (0%) | 0% | 18.2 | 771,656 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 42,422 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 43.33 per share. | 17 Feb 2026 | 42,422 | 20,590 (0%) | 0% | 43.3 | 1,838,145 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 20,030 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 44.30 per share. | 17 Feb 2026 | 20,030 | 20,590 (0%) | 0% | 44.3 | 887,329 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 21.69 per share. | 17 Feb 2026 | 20,030 | 40,620 (0%) | 0% | 21.7 | 434,451 | Common Stock |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jun 2025 | 29,747 | 29,747 | - | - | Director Stock Option (Right to Buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 May 2025 | 9,812 | 20,590 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 38.13 per share. | 27 Feb 2025 | 54,514 | 10,778 (0%) | 0% | 38.1 | 2,078,619 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.50 per share. | 27 Feb 2025 | 31,167 | 41,945 (0%) | 0% | 20.5 | 638,924 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 31,167 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 23,347 | 19,294 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 27 Feb 2025 | 23,347 | 65,292 (0%) | 0% | 19.8 | 461,570 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 37.62 per share. | 27 Feb 2025 | 19,294 | 10,778 (0%) | 0% | 37.6 | 725,840 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 19,294 | 0 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.77 per share. | 27 Feb 2025 | 19,294 | 30,072 (0%) | 0% | 19.8 | 381,442 | Common Stock |
| Exelixis Inc | Julie Anne Smith | Director | Other type of transaction at price $ 0.00 per share. | 13 Aug 2024 | 4,682 | 10,778 (0%) | 0% | 0 | Common Stock | |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 7,639 | 7,639 | - | - | Director Stock Option (Right to Buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 20,030 | 20,030 | - | - | Option (right to buy) | |
| Exelixis Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 10,015 | 15,460 (0%) | 0% | 0 | Common Stock | |
| Exelixis Inc | Julie Anne Smith | Director | Sale of securities on an exchange or to another person at price $ 21.12 per share. | 21 May 2024 | 27,280 | 5,445 (0%) | 0% | 21.1 | 576,154 | Common Stock |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2023 | 19,441 | 19,441 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 21,000 | 21,000 | - | - | Director Stock Option (Right to Buy) | |
| Stoke Therapeutics Inc | Julie Anne Smith | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 11,650 | 11,650 | - | - | Director Stock Option (Right to Buy) |